Screener
Bicara Therapeutics BCAX Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $323,462 | $96,685 |
| Prepaid expenses and other assets | 5,162 | 7,252 |
| Marketable securities | 216,291 | 318,116 |
| Total current assets | 544,915 | 422,053 |
| Property and equipment, net | 346 | 330 |
| Right of use asset – operating lease | 1,428 | 1,701 |
| Other assets | 6,910 | 6,910 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's short-term investments?
- Bicara Therapeutics (BCAX) reported short-term investments of $216.29M in Q1 2026.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Bicara Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude